Author: Peptides.GG Research Team

Epitalon (also spelled epithalon or epithalone) is a synthetic tetrapeptide with the amino-acid sequence Ala-Glu-Asp-Gly, abbreviated AEDG. It belongs to the family of short peptides studied by Vladimir Khavinson and colleagues and frequently described in the literature as a “peptide bioregulator.” This article reviews what epitalon is at the molecular level, where it originated, the telomerase and pineal-gland pathways the published research has focused on, and exactly what those studies measured in their experimental models — framed throughout as research findings rather than reader outcomes.

What epitalon is at the molecular level

Epitalon is a linear tetrapeptide built from four amino-acid residues: alanine, glutamic acid, aspartic acid, and glycine, joined in the order Ala-Glu-Asp-Gly. As a tetrapeptide it is one of the shortest peptides in the Khavinson series, and its small size is the property most often cited when researchers discuss its handling characteristics in experimental systems. It is a fully synthetic compound assembled by solid-phase peptide synthesis. It is not a tissue extract: although the broader bioregulator program began with fractions isolated from animal tissue, epitalon itself is a defined synthetic sequence rather than a purified natural product.

A closely related laboratory material is the N-acetylated analog, N-Acetyl Epitalon (NA-Epitalon), in which an acetyl group caps the N-terminus. This modification is commonly described in peptide chemistry as a strategy to alter a peptide’s stability profile, and NA-Epitalon is generally presented as a stabilized analog of the parent AEDG sequence for research handling.

Origin and structure of the AEDG sequence

Epitalon emerged from a long-running Russian research program on short peptides associated with the pineal gland and thymus. That program proposed that very short peptide sequences could interact with regulatory regions of the genome, and AEDG was advanced as a synthetic representative of the pineal-associated activity the group was studying. In the published model, the four-residue sequence is short enough that researchers have examined whether it can interact directly with DNA and with gene-promoter sites rather than acting through a conventional cell-surface receptor. The compactness of the Ala-Glu-Asp-Gly chain — and the charged glutamate and aspartate residues it carries — is central to how the literature describes its proposed interactions with nucleotide sequences.

The telomerase and pineal pathways the literature focuses on

The defining angle of the epitalon literature is its reported association with telomerase, the enzyme that adds repeat DNA to chromosome ends, and with telomere length in cultured cells. A second recurring theme is the pineal gland and its melatonin-producing axis, reflecting the peptide’s origin in pineal research. Across these papers the mechanism most often proposed is a direct interaction between the short peptide and specific promoter or telomere-associated DNA sequences, which the authors frame as a possible epigenetic-style mode of action distinct from classic receptor signaling. The sections below summarize what the cited studies actually measured in their research models, with no implied outcome for any individual.

What published research measured

• In cultured human somatic cells (fibroblast cultures), Khavinson and colleagues reported induction of telomerase activity and elongation of telomeres in the treated cultures, alongside an increase in the number of population doublings the cultures underwent — Bull Exp Biol Med, 2003 (Khavinson et al.).
• In a long-term observational program on peptide preparations of the pineal gland and thymus, the authors reported survival and mortality statistics in their elderly study cohorts over multiple years of follow-up — Neuro Endocrinol Lett, 2003 (Khavinson et al.).
• Using a molecular-modeling and binding framework, the group examined how short cell-penetrating peptides of this class could interact with gene-promoter sites, presenting a model of sequence-specific peptide–DNA contacts — Bull Exp Biol Med, 2013 (Khavinson et al.).
• In a review of pineal-gland aging, the authors compiled morphological and molecular changes in the pineal across age and discussed where peptide bioregulators were studied within that context — Fiziol Cheloveka, 2012 (Khavinson et al.).
• In hypophysectomized young and old birds, researchers measured changes in thymus morphology following administration of the AEDG sequence and the related Lys-Glu-Asp-Gly peptide, reporting tissue-structure differences between groups — Bull Exp Biol Med, 2013 (Pateyk et al.).

Why the research framing matters

Much of the epitalon literature comes from a single research group and is concentrated in a small number of journals, and several of the headline findings — particularly the cell-culture telomerase results — have not been broadly replicated by independent laboratories. For anyone surveying this compound, that means the published results describe what was measured in specific cell cultures, animal models, and observational cohorts; they are not generalizable claims about effects in people. Reading each citation as “what this study measured in its model” rather than as an outcome keeps the picture accurate. For the wider context of this peptide family, see our overview, Khavinson Bioregulators: the Complete Guide.

Frequently asked questions

What is epitalon?

Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It is one of the short peptide “bioregulators” studied by Khavinson and colleagues, and in the literature it is most associated with telomerase and pineal-gland research models.

What does the AEDG abbreviation mean?

AEDG is the single-letter code for the four amino acids in the chain: A for alanine, E for glutamic acid, D for aspartic acid, and G for glycine, in that order. It is simply a shorthand for the Ala-Glu-Asp-Gly sequence.

Is epitalon a natural extract or a synthetic peptide?

Epitalon is a fully synthetic peptide. While the broader bioregulator program originated with fractions from animal tissue, epitalon itself is a defined sequence made by solid-phase peptide synthesis rather than a purified natural extract.

Why is epitalon linked to telomerase in the literature?

The most frequently cited paper reported that the peptide induced telomerase activity and telomere elongation in human cell cultures (Khavinson et al., Bull Exp Biol Med, 2003). That cell-culture result is the main reason telomerase is the recurring theme in discussions of this compound.

How is epitalon different from NA-Epitalon?

NA-Epitalon is the N-acetylated analog of the same AEDG sequence, with an acetyl group on the N-terminus. It is generally described as a stabilized analog of the parent peptide for research handling. The two can be compared on the NA-Epitalon product page and the Epitalon product page.

How well replicated are the epitalon findings?

Much of the published work comes from one research group and a small set of journals, and key findings such as the cell-culture telomerase results have not been widely reproduced by independent labs. The literature is best read as a set of model-specific measurements rather than established, generalizable conclusions.

References

1. Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003. PMID: 12937682.
2. Khavinson VKh, et al. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003. PMID: 14523363.
3. Khavinson VKh, et al. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med. 2013. PMID: 23484211.
4. Khavinson VKh, et al. Morphofunctional and molecular bases of pineal gland aging. Fiziol Cheloveka. 2012. PMID: 22567846.
5. Pateyk AV, et al. Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bull Exp Biol Med. 2013. PMID: 23658898.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

PT-141 — the research name for bremelanotide — is a synthetic cyclic heptapeptide that acts as an agonist at the melanocortin receptors, most notably MC4R. It is a close structural relative of Melanotan II and one of the most thoroughly characterized melanocortin agonists in the published literature, studied in both receptor-binding work and human clinical trials. This article covers what PT-141 is at the molecular level, where it came from, how it engages the central melanocortin system, what published research has measured, and how it relates to its parent compound.

What PT-141 is at the molecular level

PT-141 is a cyclic heptapeptide — a seven-residue backbone closed into a ring by a lactam bridge rather than left as a free linear chain. The cyclization is not incidental: the bridge locks the molecule into a fixed conformation, the feature pharmacology studies associate with its potency and durability at melanocortin receptors relative to the short-lived native hormone it descends from.

Functionally it is a melanocortin receptor agonist — a ligand that binds and activates members of that receptor family. Molinoff et al. (Ann N Y Acad Sci, 2003) described it as a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) engaging receptors expressed predominantly in the central nervous system, with its activity at MC3R and MC4R as the basis of its pharmacological profile.

Origin: derived from Melanotan II and α-MSH

PT-141 sits at the end of a well-documented design lineage that begins with α-MSH, the 13-residue endogenous melanocortin peptide, and runs through Melanotan II — itself a cyclic, truncated, lactam-bridged analog of α-MSH. PT-141 is the deaminated metabolite of Melanotan II: structurally it corresponds to Melanotan II with the C-terminal amide replaced by a free carboxylic acid, so the two share essentially the same ring scaffold and differ at a single terminal position.

That close kinship is why the two are so frequently discussed together. For a structural comparison of the broader Melanotan family — linear versus cyclic backbones and receptor selectivity — see our companion article on Melanotan 1 vs Melanotan 2. In short, PT-141 inherits the constrained cyclic heptapeptide chassis of Melanotan II, with the C-terminal modification distinguishing it as its own characterized molecule.

Melanocortin-receptor mechanism: a central, MC4R-led profile

The defining feature of PT-141 in the literature is that it is studied as a centrally acting melanocortin agonist. The melanocortin receptors are a family of five G-protein-coupled receptors, MC1R through MC5R. Of these, MC3R and MC4R are concentrated in the brain — particularly in hypothalamic and limbic regions — and MC4R is the receptor most associated with PT-141’s central pharmacology in published work (Molinoff et al., Ann N Y Acad Sci, 2003).

This central, receptor-mediated mechanism is what investigators contrast with the peripheral action of PDE5 inhibitors such as sildenafil, which act downstream in vascular tissue by inhibiting phosphodiesterase type 5 to alter local blood flow. PT-141 instead operates centrally, engaging brain melanocortin receptors — so the literature treats the two as mechanistically distinct classes: central melanocortin signaling versus peripheral vascular enzyme inhibition.

What published research and trials measured

PT-141 / bremelanotide has been evaluated across early-phase pharmacology studies and large randomized clinical trials. The following summarizes what the cited studies measured in their research populations — not outcomes attributed to any reader.

• Receptor and pharmacology characterization. Molinoff et al. characterized PT-141 as a synthetic melanocortin agonist whose engagement of centrally expressed MC3R and MC4R forms the basis of its activity, distinguishing it from peripherally acting agents (Molinoff et al., Ann N Y Acad Sci, 2003).
• Intranasal pharmacokinetics and pharmacodynamics. A double-blind, placebo-controlled study gave intranasal PT-141 to healthy male volunteers and participants with mild-to-moderate erectile dysfunction, measuring safety, plasma pharmacokinetics, and RigiScan-recorded erectile response (Diamond et al., Int J Impot Res, 2004).
• Subcutaneous administration in Viagra non-responders. Rosen et al. evaluated subcutaneous PT-141 in healthy male subjects and in patients reporting an inadequate response to Viagra, again using RigiScan to quantify the erectile response alongside safety and pharmacokinetic measures (Rosen et al., Int J Impot Res, 2004).
• Phase 3 trials in female research subjects (RECONNECT). Two identical randomized, double-blind, placebo-controlled Phase 3 trials studied subcutaneous bremelanotide in premenopausal women clinically diagnosed with hypoactive sexual desire disorder, with co-primary endpoints of change from baseline on the Female Sexual Function Index desire domain and a Female Sexual Distress Scale item (Kingsberg et al., Obstet Gynecol, 2019).
• Long-term safety follow-up. A subsequent open-label extension measured long-term safety and tolerability in the same population, reporting the most common treatment-emergent adverse events as tolerability-related and predominantly mild to moderate (Simon et al., Obstet Gynecol, 2019).

Across these studies, bremelanotide is the melanocortin agonist that progressed furthest in clinical research — the compound studied clinically for hypoactive sexual desire disorder in premenopausal women, the indication the RECONNECT program was designed around.

How PT-141 relates to Melanotan II

The cleanest way to situate PT-141 is as the deaminated, carboxyl-terminal form of Melanotan II: the same lactam-bridged ring, differing only where Melanotan II carries a C-terminal amide and PT-141 a free acid. That single change defines PT-141 as a distinct research compound, while the shared scaffold explains why both are broad melanocortin agonists engaging MC4R among other subtypes. Melanotan II is most often discussed in pigmentation-related melanocortin research; PT-141 is the analog whose published record centers on central MC3R/MC4R pharmacology and the human trials summarized above.

Frequently asked questions

What is PT-141?

PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. In the published literature it is characterized chiefly through its activity at the centrally expressed MC3R and MC4R subtypes (Molinoff et al., 2003).

Is PT-141 the same as bremelanotide?

Yes. “PT-141” and “bremelanotide” refer to the same molecule. PT-141 is the original research designation; bremelanotide is the assigned nonproprietary name used in the later clinical trial literature.

How is PT-141 related to Melanotan II?

PT-141 is the deaminated metabolite of Melanotan II. The two share the same cyclic, lactam-bridged heptapeptide scaffold derived from α-MSH and differ at the C-terminus, where Melanotan II has an amide and PT-141 has a free carboxylic acid.

Which melanocortin receptor is PT-141 associated with?

Its central pharmacology is most associated with MC4R, with MC3R also implicated — the subtypes concentrated in hypothalamic and limbic regions of the brain (Molinoff et al., 2003).

How does PT-141’s mechanism differ from a PDE5 inhibitor?

The literature describes PT-141 as a centrally acting melanocortin agonist that engages brain receptors, whereas PDE5 inhibitors such as sildenafil act peripherally by inhibiting phosphodiesterase type 5 in vascular tissue — two mechanistically distinct classes.

What did the clinical trials of bremelanotide measure?

The Phase 3 RECONNECT program measured change from baseline on validated questionnaire endpoints — the Female Sexual Function Index desire domain and a Female Sexual Distress Scale item — in premenopausal women clinically diagnosed with hypoactive sexual desire disorder (Kingsberg et al., 2019), and a follow-up study measured long-term safety in the same population (Simon et al., 2019).

References

1. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003. PMID: 12851303.
2. Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PMID: 14963471.
3. Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PMID: 14999221.
4. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019. PMID: 31599840.
5. Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019. PMID: 31599847.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

IGF-1 LR3 is not insulin-like growth factor 1 itself but a deliberately modified version of it — an engineered analog that differs from the natural molecule at two defined points in its sequence. The two changes are not cosmetic: together they were designed to alter how the molecule interacts with a family of carrier proteins called the IGF binding proteins (IGFBPs). The name encodes the changes — “Long” for an added N-terminal extension and “R3’ for an arginine swapped in at position 3. This overview describes what IGF-1 LR3 is at the molecular level, what each of those two modifications does to its binding behavior, and what the published research has measured in laboratory systems.

What IGF-1 LR3 is — a modified analog of IGF-1

Native insulin-like growth factor 1 is a 70–amino-acid single-chain polypeptide that is structurally related to proinsulin. It is the central effector of the somatotropic axis and signals through the type 1 IGF receptor (IGF-1R), a cell-surface receptor tyrosine kinase. In the body, however, the great majority of IGF-1 is not free: it circulates bound to high-affinity carrier proteins, and that bound fraction is largely sequestered away from the receptor.

IGF-1 LR3 is a recombinant analog of that molecule — the same IGF-1 backbone carrying two engineered modifications. The full descriptive name is Long [Arg³]-IGF-1, which spells out exactly what was done: an arginine substitution at residue 3 (“R3”) and an additional 13-residue peptide extension fused to the N-terminus (“Long”). The analog was characterized structurally by NMR spectroscopy, which confirmed that the extended, substituted molecule retains the core fold of native IGF-1 (Laajoki et al., FEBS Lett, 1997). It is the binding behavior, not the overall shape, that the modifications were intended to change.

The two modifications: Arg³ substitution and the 13-residue extension

The first modification is a single-residue swap. At position 3 of the IGF-1 sequence, the native amino acid is glutamate; in the analog it is replaced by arginine — the “[Arg³]” or “R3” part of the name. Position 3 sits within the region of IGF-1 that contacts the IGF binding proteins, so changing the side chain there directly perturbs that interface.

The second modification is the “Long” part: a 13-amino-acid peptide extension added to the amino-terminal end of the chain. This N-terminal extension is derived from a methionyl-porcine-growth-hormone leader sequence and is a separate change from the Arg³ substitution. Stacking the two modifications onto one molecule is what defines the analog as “Long R3” IGF-1, distinguishing it from simpler single-modification variants such as plain [Arg³]-IGF-1 or Long-IGF-1 on their own.

Why those modifications reduce IGFBP binding and extend half-life

The IGF binding proteins are a family of six high-affinity carrier proteins (IGFBP-1 through IGFBP-6) that bind IGF-1 in the circulation and in tissues. Their role is to control how much IGF-1 is free to engage the receptor: a molecule held by an IGFBP is, for the moment, not available to bind IGF-1R, and the binding proteins also modulate the molecule’s clearance and distribution (Firth & Baxter, Endocr Rev, 2002). The IGFBPs are therefore the gatekeepers of IGF-1 availability.

Both engineered changes in IGF-1 LR3 target that gate. The Arg³ substitution sits in the binding-protein contact region, and the N-terminal extension adds further steric and electrostatic interference at the same interface. The combined result, as reported in the foundational characterization of these analogs, is a markedly reduced affinity for the IGF binding proteins while affinity for the IGF-1 receptor is largely preserved (Francis et al., J Mol Endocrinol, 1992). Because the analog escapes sequestration by the IGFBPs, a larger fraction of it remains in the free, receptor-available state, and it is not subject to the same binding-protein–mediated handling that governs the native molecule — the structural basis for the longer functional half-life attributed to it in the literature.

What published research measured about IGF-1R signaling

The research on these analogs is laboratory work in cell-based and biochemical systems. The findings below are reported strictly as what each cited study measured in its research model:

• Reduced binding-protein affinity with retained receptor binding. The study that introduced this class of fusion-protein analogs measured their affinity for the IGF binding proteins and for the type 1 IGF receptor, reporting sharply lower IGFBP affinity alongside preserved receptor binding, and used that dissociation to weigh the relative contributions of binding-protein evasion versus receptor engagement to the enhanced potency observed in cultured cells (Francis et al., J Mol Endocrinol, 1992).
• Retention of the native fold. Multidimensional NMR spectroscopy of ¹⁵N-labelled Long-[Arg³]-IGF-1 measured its secondary structure and reported that the analog conserves the core three-helix architecture of native IGF-1 despite the substitution and the N-terminal extension (Laajoki et al., FEBS Lett, 1997).
• The receptor pathway engaged. The intracellular signaling the type 1 IGF receptor activates on ligand binding — receptor-kinase autophosphorylation and recruitment of IRS adaptors feeding the PI3K–Akt and Ras–MAPK cascades — is documented in the IGF-1R signaling literature (Hakuno & Takahashi, J Mol Endocrinol, 2018). This is the receptor system the analog was engineered to reach more readily, not an effect measured for IGF-1 LR3 in any organism.
• Binding-protein control of availability. The premise that motivated the modifications — that the IGFBPs govern how much IGF-1 is free and receptor-available — is established in the binding-protein review literature (Firth & Baxter, Endocr Rev, 2002).

Each of these is a measurement made in a biochemical assay, a structural experiment, or a cell-based system. They describe what the cited investigators recorded; none is a statement about an effect in a person or an animal.

How it differs from native IGF-1

IGF-1 LR3 is best summarized by what it shares with native IGF-1 and what it does not. It shares the receptor target: like the natural molecule, it is studied as a ligand of the type 1 IGF receptor, with receptor affinity reported as broadly retained (Francis et al., J Mol Endocrinol, 1992). What it does not share is the binding-protein relationship — native IGF-1 is heavily bound and regulated by the IGFBPs, whereas the analog, by virtue of its Arg³ substitution and 13-residue extension, binds those proteins far more weakly. It is also physically larger than the 70-residue parent. In short, IGF-1 LR3 is native IGF-1 re-engineered to step out from under IGFBP control — the single structural theme that ties its name, its design, and its published biochemistry together.

Frequently asked questions

What is IGF-1 LR3?

IGF-1 LR3 is a modified analog of insulin-like growth factor 1. Its full name is Long [Arg³]-IGF-1, reflecting two engineered changes to the native sequence: an arginine substituted at position 3 and a 13-amino-acid extension added to the N-terminus.

What does “LR3” stand for?

“L” (or “Long”) refers to the 13-residue N-terminal peptide extension, and “R3” refers to the arginine (R) substituted in at residue 3, replacing the glutamate found there in native IGF-1. Together they name the two modifications that define the analog.

How is IGF-1 LR3 different from regular IGF-1?

It carries two modifications native IGF-1 does not: the Arg³ swap and the N-terminal extension. The published characterization reports that these changes sharply lower its affinity for the IGF binding proteins while largely preserving binding to the type 1 IGF receptor (Francis et al., 1992).

Why do the modifications reduce binding to the IGF binding proteins?

Position 3 lies within the region of IGF-1 that contacts the binding proteins, and the N-terminal extension adds further interference at that same interface. The combined effect measured in the literature is markedly reduced IGFBP affinity, which leaves a larger fraction of the analog in the free, receptor-available state.

Does IGF-1 LR3 keep the same shape as IGF-1?

NMR structural work on Long-[Arg³]-IGF-1 reported that the analog retains the core fold of native IGF-1 despite the substitution and the extension (Laajoki et al., 1997). The modifications change its binding behavior, not its overall architecture.

Has IGF-1 LR3 been studied in humans?

The published research on this analog is laboratory work — biochemical binding assays, structural spectroscopy, and cell-based systems. The binding-protein, structural, and receptor-signaling findings cited here were measured in those research models, not in human subjects.

References

1. Francis GL, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992. PMID: 1378742.
2. Laajoki LG, et al. Secondary structure determination of 15N-labelled human Long-[Arg-3]-insulin-like growth factor 1 by multidimensional NMR spectroscopy. FEBS Letters. 1997. PMID: 9450557.
3. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews. 2002. PMID: 12466191.
4. Hakuno F, Takahashi SI. IGF1 receptor signaling pathways. Journal of Molecular Endocrinology. 2018. PMID: 29535161.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

Kisspeptin-10 is the shortest biologically active member of the kisspeptin family — a ten-amino-acid fragment carved from the C-terminus of the larger KISS1-gene product. That single structural fact is what the literature is built on, because the C-terminal decapeptide is the part that binds and activates the receptor KISS1R (formerly the orphan receptor GPR54). This overview covers what kisspeptin-10 is at the molecular level, the receptor it acts on, its place upstream of gonadotropin-releasing hormone (GnRH) in the hypothalamic-pituitary-gonadal (HPG) axis as measured in research, and how the –10 fragment relates to the longer kisspeptin forms such as kisspeptin-54.

What kisspeptin-10 is

Kisspeptin-10 is the C-terminal ten-amino-acid fragment of kisspeptin, the peptide product of the KISS1 gene — a gene originally described as a metastasis suppressor. Its protein product is processed into a set of related peptides, collectively the kisspeptins, that share a common amidated C-terminal sequence (Kotani et al., J Biol Chem, 2001).

That shared C-terminus is the functionally important part. When researchers isolated the natural ligands of GPR54, the activity tracked to this conserved tail rather than to the full-length precursor. Kisspeptin-10 is, in effect, that minimal active tail on its own — the smallest fragment that retains receptor-binding activity in the original characterization. This overview keeps the chemistry qualitative; the exact residue sequence is best read from the primary source.

The receptor: KISS1R / GPR54

Kisspeptin-10 acts on a single, well-defined target: KISS1R, a G protein-coupled receptor known as GPR54 before its endogenous ligand was identified. The receptor was first an orphan — a GPCR with no known natural ligand — and the work pairing it with the KISS1 peptides gave it both a ligand and a name (Kotani et al., J Biol Chem, 2001).

In that founding study, the kisspeptin peptides were reported to act as agonists at GPR54, with the C-terminal fragments retaining activity at the receptor. The ligand–receptor pairing is the anchor for everything downstream: kisspeptin-10 is studied specifically as a KISS1R agonist, and the receptor’s expression on the neurons that release GnRH is what places this signaling step where it sits in the axis.

Where it sits: upstream of GnRH in the HPG axis

The reason kisspeptin-10 is studied as a neuroendocrine peptide is its position in the HPG axis. The control hierarchy runs from the hypothalamus — which releases GnRH — to the pituitary, which releases the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Research placed kisspeptin signaling one step above GnRH: KISS1R is expressed on GnRH neurons, and kisspeptin acts on them as a regulator of GnRH secretion.

This was demonstrated directly. One mechanistic study reported that kisspeptin directly stimulates GnRH release via GPR54, characterizing the peptide as an upstream activator of the GnRH neuron rather than acting at the pituitary (Messager et al., Proc Natl Acad Sci U S A, 2005). The genetic side came from human and mouse work showing that loss-of-function mutations in GPR54 were associated with idiopathic hypogonadotropic hypogonadism and disrupted puberty (Seminara et al., N Engl J Med, 2003). These are findings measured in those research and clinical-genetics models; they are not outcomes predicted for any individual.

What published research has measured

The kisspeptin literature spans cell, animal, and human-physiology work. The findings below are reported strictly as what each cited study measured in its research model:

• Ligand–receptor identification. The founding study measured that the KISS1-gene peptides act as natural agonist ligands at the orphan receptor GPR54, with the C-terminal fragment retaining activity (Kotani et al., J Biol Chem, 2001).
• Direct GnRH stimulation. A mechanistic study measured that kisspeptin directly stimulates GnRH release through GPR54, identifying the GnRH neuron as the site of action upstream of the pituitary (Messager et al., Proc Natl Acad Sci U S A, 2005).
• Genetic requirement in the axis. Human and mouse work measured that GPR54 loss-of-function was associated with hypogonadotropic hypogonadism and abnormal puberty (Seminara et al., N Engl J Med, 2003).
• Measured LH response to administration. In a human-physiology study, administration of a kisspeptin form was measured to be associated with increased circulating LH and other gonadotropin-axis hormones, quantifying the axis response in the research setting (Dhillo et al., J Clin Endocrinol Metab, 2005).

Across this work, the recurring theme is a single signaling step: kisspeptin engages KISS1R on GnRH neurons, and the measured consequence is altered GnRH and downstream gonadotropin (LH) output — all characterized within the cited research and clinical-genetics systems.

How kisspeptin-10 relates to kisspeptin-54 and the longer forms

The KISS1 gene product is processed into several kisspeptin peptides of different lengths that share the same C-terminal sequence. The longest commonly referenced form, kisspeptin-54, is a 54-amino-acid peptide; shorter fragments — kisspeptin-14, kisspeptin-13, and the decapeptide kisspeptin-10 — are progressively trimmed pieces ending in that same conserved, receptor-binding tail (Kotani et al., J Biol Chem, 2001).

The practical research point is that the C-terminal decapeptide is the minimal active unit: kisspeptin-10 carries the part the original work showed retains agonist activity. Kisspeptin-54 is the form used in some human-physiology administration studies (Dhillo et al., J Clin Endocrinol Metab, 2005), while kisspeptin-10 is the compact fragment most often used to probe the receptor and pathway in vitro and in animal models — different lengths of one signaling sequence, sharing the activating C-terminus that defines the family.

Frequently asked questions

What is kisspeptin-10?

Kisspeptin-10 is the C-terminal ten-amino-acid fragment of kisspeptin, the peptide product of the KISS1 gene, and the shortest fragment that retains agonist activity at the receptor KISS1R (formerly GPR54) in the original characterization (Kotani et al., 2001).

What receptor does kisspeptin-10 act on?

It acts on KISS1R, a G protein-coupled receptor formerly known as the orphan receptor GPR54. The KISS1-gene peptides were identified as the natural agonist ligands of this receptor, giving the previously orphan GPR54 its endogenous ligand (Kotani et al., 2001).

How does kisspeptin-10 relate to the HPG axis?

KISS1R is expressed on the GnRH-releasing neurons of the hypothalamus, which places kisspeptin signaling one step above GnRH in the hypothalamic-pituitary-gonadal axis. Research measured that kisspeptin directly stimulates GnRH release via GPR54 (Messager et al., 2005), positioning it as an upstream regulator of the GnRH neuron in those models.

What did research measure about GPR54 and reproduction?

Human and mouse studies measured that loss-of-function mutations in GPR54 were associated with idiopathic hypogonadotropic hypogonadism and disrupted puberty (Seminara et al., 2003) — a finding characterized in genetic-model and clinical-genetics systems.

What is the difference between kisspeptin-10 and kisspeptin-54?

Both are processed from the same KISS1 gene product and share the same active C-terminal sequence. Kisspeptin-54 is the 54-amino-acid form; kisspeptin-10 is the trimmed C-terminal decapeptide — the minimal active unit that retains receptor binding (Kotani et al., 2001).

Has kisspeptin been studied in humans?

Yes, at the level of axis physiology. A human-physiology study measured that administration of a kisspeptin form was associated with an increase in circulating LH and related gonadotropin-axis hormones (Dhillo et al., 2005) — measurements of the axis response in the research setting, not effects established for any individual.

References

1. Kotani M, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001. PMID: 11457843.
2. Messager S, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci U S A. 2005. PMID: 15665093.
3. Seminara SB, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003. PMID: 14573733.
4. Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005. PMID: 16174713.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

GHK-Cu is the copper(II) complex of a short, naturally occurring tripeptide — glycyl-L-histidyl-L-lysine, abbreviated GHK. It is best understood as a copper-binding peptide: the sequence carries a built-in affinity for copper ions, and the resulting peptide–metal complex is the molecule studied in the laboratory literature. This overview covers what GHK-Cu is at the structural level, the copper-binding chemistry that defines it, the mechanisms research has focused on, and what specific published studies actually measured in their experimental models. The compound is available on its GHK-Cu product page, and the same molecule appears as a component of two multi-peptide research blends discussed near the end of this article.

What GHK-Cu is

At its core, GHK is a tripeptide — a chain of just three amino acids: glycine, L-histidine, and L-lysine, in that order (Gly-His-Lys). It was originally isolated from human plasma, which makes it a naturally occurring sequence rather than a designed drug. The “-Cu” suffix denotes that the peptide is supplied as a complex with a single copper(II) ion, written chemically as GHK-Cu²⁺. The copper is not an incidental additive — it is the defining feature of the molecule, because the biochemistry researchers have studied is, in large part, the biochemistry of a peptide-bound copper ion being carried into a biological system.

Structurally, GHK-Cu has two parts that always travel together: the small tripeptide scaffold and the metal ion it chelates. That pairing is why the compound is described as a copper peptide, and why the literature regards the copper-binding behavior as central rather than peripheral.

The copper-binding chemistry that defines it

The reason GHK binds copper so well comes down to its middle residue. Histidine carries an imidazole side chain whose nitrogen atoms are strong coordinating groups for transition-metal ions, and in GHK that histidine sits flanked by the free amino terminus of glycine and the side-chain amine of lysine. Together these donor atoms form a coordination geometry that wraps around a copper(II) ion and holds it in a stable square-planar arrangement. The result is a high-affinity complex: GHK does not merely sit near copper, it chelates it.

This chelation gives GHK-Cu its distinct identity. Free copper ions are reactive and tightly controlled in biological systems, whereas peptide-bound copper is presented in a more regulated form. In the research literature, GHK-Cu is frequently framed as a physiological copper-binding peptide that participates in copper-dependent biochemistry. Because the metal and the peptide function as a single unit, studies almost always describe the complexed GHK-Cu form rather than the bare peptide.

The mechanisms research focuses on

Two broad mechanistic themes dominate the published GHK-Cu literature, and both are described here strictly as what investigators measured in cell, tissue, and animal models — not as outcomes attributed to any person.

The first theme is extracellular-matrix (ECM) and collagen remodeling. In fibroblast and wound models, researchers have measured changes in the production and turnover of matrix components — collagen, glycosaminoglycans, proteoglycans — and in the enzymes that remodel that matrix. The work positions GHK-Cu as a molecule that experimental systems respond to with altered ECM-related activity.

The second theme is broad gene-expression modulation. Transcriptome-scale analyses — including work that ran GHK against the Broad Institute Connectivity Map, a large database of gene-expression signatures — reported that the peptide is associated with shifts in the expression of a wide set of genes in cultured human cells. This is the angle emphasized in Pickart’s reviews: rather than a single target, the published gene data describe GHK as a modulator registered across many transcriptional pathways at once. In every case the measurement belongs to the cited model, and the citation is the claim.

What published research measured

The following points summarize specific findings from the peer-reviewed literature. Each describes a measurement made in a defined research model, with its citation:

• In cultured dermal fibroblasts, the tripeptide-copper complex was reported to increase levels of matrix metalloproteinase-2 (MMP-2), an enzyme involved in extracellular-matrix remodeling, in conditioned media (Siméon et al., Life Sci, 2000).
• In an experimental wound model, GHK-Cu treatment was associated with modulated mRNA levels of the small proteoglycans decorin and biglycan and altered glycosaminoglycan expression during repair (Siméon et al., J Invest Dermatol, 2000).
• A review of GHK-Cu biochemistry catalogued cell- and tissue-model reports of effects on the expression of genes tied to collagen, elastin, and glycosaminoglycan synthesis and to tissue remodeling (Pickart & Margolina, BioMed Research International, 2015).
• A later review synthesized transcriptome-scale gene data, summarizing Connectivity Map analyses in which GHK was associated with shifts across a large number of human genes (Pickart & Margolina, Int J Mol Sci, 2018).
• A focused analysis examined GHK’s association with the expression of genes relevant to nervous-system function, again drawing on Connectivity Map gene-expression signatures (Pickart et al., Brain Sci, 2017).

Taken together, these are descriptions of laboratory observations — what the molecule did in fibroblast cultures, wound models, and transcriptome databases — not statements about effects in people.

How GHK-Cu relates to the GLOW and KLOW blends

GHK-Cu is sold both on its own and as one ingredient inside two multi-component research blends, which is why it surfaces in searches for those products. The relationship is purely additive at the level of ingredients:

• GLOW pairs GHK-Cu with BPC-157 and TB-500 — three chemically unrelated peptides supplied in one vial. The chemistry of each is covered in our explainer, What Is the GLOW Stack?
• KLOW is the same three plus a fourth peptide, KPV, a lysine-proline-valine tripeptide. Its components are broken down in What Is the KLOW Blend?

In both blends, GHK-Cu contributes exactly the copper-binding tripeptide described above; the blend name is simply an acronym for the components co-located together, not a description of any combined result. If a study design calls only for the copper peptide on its own, the standalone GHK-Cu is the relevant material.

Frequently asked questions

What does GHK-Cu stand for?

GHK-Cu denotes the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. “GHK” is the single-letter shorthand for that glycine–histidine–lysine amino-acid sequence, and “Cu” is the chemical symbol for copper, the metal ion the peptide binds.

Why is copper part of the molecule?

The histidine residue in the middle of the GHK sequence has an imidazole side chain that coordinates copper(II) ions strongly. The peptide therefore chelates a copper ion to form a stable complex, and that complexed GHK-Cu form — not the bare peptide — is what the research literature studies.

Is GHK-Cu naturally occurring?

The underlying GHK tripeptide was originally isolated from human plasma and has also been reported in saliva and urine, so the sequence occurs naturally. The material supplied for research is produced synthetically and complexed with copper.

What have studies measured with GHK-Cu?

Published work has measured changes in extracellular-matrix activity — for example matrix metalloproteinase-2, glycosaminoglycans, and the proteoglycans decorin and biglycan — in fibroblast and wound models, plus broad shifts in gene expression in transcriptome analyses. These are findings within those specific research models.

How is GHK-Cu different from GHK?

GHK is the tripeptide on its own; GHK-Cu is that same tripeptide bound to a copper(II) ion. Because the copper-binding behavior is central to the biochemistry researchers study, the literature generally refers to the copper-complexed GHK-Cu form.

Is GHK-Cu approved for human use?

No. GHK-Cu is a research compound characterized in laboratory, cell, and animal models, and the product discussed here is intended for laboratory research purposes only, not for human or veterinary use.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMID: 29986520.
2. Pickart L, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMID: 26236730.
3. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017. PMID: 28212278.
4. Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000. PMID: 11045606.
5. Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000. PMID: 11121126.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

Most signaling peptides are encoded in the cell’s nuclear DNA. MOTS-c is one of the exceptions: it is a short peptide whose coding sequence sits inside the mitochondrial genome rather than the nucleus, which is why it is classed as a mitochondrial-derived peptide (MDP). That single fact — where its gene is — is what the literature builds on, because it ties the peptide directly to the cell’s energy machinery. This overview covers what MOTS-c is at the molecular level, where it comes from, and what published studies have measured in research models, including its reported link to the AMPK energy-sensing pathway.

What MOTS-c is

MOTS-c is a short peptide — in its first characterization, a 16-amino-acid peptide (Lee et al., Cell Metab, 2015). The name is an abbreviation: Mitochondrial ORF of the Twelve S rRNA type-c, which captures the two facts that define it. “ORF” (open reading frame) marks it as a coded peptide, and “Twelve S rRNA” names the stretch of the mitochondrial genome the code is read from.

It is grouped with research peptides on vendor lists, but its defining feature is not a chemical modification or an analog relationship to a hormone — it is its genomic address. This overview keeps the chemistry qualitative: MOTS-c is a small, mitochondrially encoded peptide, and the precise residue-level details are best read from the primary source.

Where it comes from: a mitochondrial-derived peptide

Nearly every signaling peptide a cell makes is transcribed from a gene in the nuclear genome. MOTS-c is different: its coding sequence is a small open reading frame located within the 12S ribosomal RNA region of mitochondrial DNA (mtDNA) — the mitochondrion’s own separate, circular genome (Lee et al., Cell Metab, 2015). That origin is the reason for the “mitochondrial-derived” label.

This places MOTS-c in the mitochondrial-derived peptide (MDP) family — a class encoded within mtDNA rather than the nucleus, the subject of a growing review literature (Mohtashami et al., Int J Mol Sci, 2022). The reported significance is that the mitochondrion does not only generate energy; it also encodes peptides that participate in signaling. As one of the most-studied MDPs, MOTS-c is positioned by its mtDNA origin as a candidate messenger between the mitochondria and the cell.

• Genomic location: a small open reading frame inside the 12S rRNA region of mitochondrial DNA (Lee et al., 2015).
• Family: mitochondrial-derived peptides (MDPs), encoded by mtDNA rather than the nuclear genome (Mohtashami et al., 2022).
• Class framing: an endogenous mitochondrial signaling peptide, not an analog of a known nuclear-encoded hormone.

The reported AMPK link

The mechanism MOTS-c is most associated with runs through AMP-activated protein kinase (AMPK) — a central enzyme often called the cell’s energy sensor, because it responds to the cell’s energy balance and adjusts metabolic gene programs accordingly. In the originating study, the authors reported that MOTS-c acts on the folate–methionine (one-carbon) pathway and connected purine biosynthesis, with this engagement associated with activation of AMPK in their model systems (Lee et al., Cell Metab, 2015).

It is worth reading that link precisely. The 2015 work reported that MOTS-c activated the AMPK pathway and was associated with metabolic changes in mice and cell models — including effects on insulin sensitivity and resistance to diet-induced obesity (Lee et al., Cell Metab, 2015). These are outcomes measured in those non-human research systems — not effects established in humans, and not a result predicted for any individual.

What published research has measured

The MOTS-c literature is preclinical — conducted in animal and cell-based systems. The findings below are reported strictly as what each cited study measured in its research model:

• Metabolic homeostasis and AMPK. The founding study measured that MOTS-c engaged the folate–AMPK axis and, in mice and cells, was associated with improved insulin sensitivity and reduced diet-induced obesity and insulin resistance (Lee et al., Cell Metab, 2015).
• Nuclear translocation under stress. A later study measured that, under metabolic stress, MOTS-c moved into the cell nucleus and was associated with changes in nuclear gene expression — characterizing it as a stress-responsive transcriptional regulator (Kim et al., Cell Metab, 2018).
• Exercise and age-related decline. In aging mice, MOTS-c was measured to be exercise-induced, with administration associated with changes in physical performance and muscle measures across young, middle-aged, and old animals (Reynolds et al., Nat Commun, 2021).
• MDP family context. MOTS-c’s role within the mitochondrial-derived-peptide class is summarized in the review literature (Mohtashami et al., Int J Mol Sci, 2022).

Across this work, the recurring theme is the energy-sensing pathway: MOTS-c engages AMPK and its downstream metabolic gene programs, and under stress can relocate to the nucleus to influence gene expression — all characterized to date only in non-human research systems.

Why the mitochondrial origin matters for the research framing

The reason MOTS-c attracts study is that its source and its function line up. A peptide encoded inside the mitochondrial genome, acting on the master energy-sensing kinase, is a clean candidate for a signal that reports mitochondrial energy status to the wider cell — the hypothesis the literature has been testing. That framing makes MOTS-c best understood as a research tool for probing mitochondrial signaling and the AMPK pathway, characterized so far only in cell and animal models.

Frequently asked questions

What is MOTS-c?

MOTS-c is a short peptide that belongs to the mitochondrial-derived-peptide (MDP) family. Unlike most signaling peptides, which are encoded in nuclear DNA, its coding sequence sits inside the mitochondrial genome — specifically within the 12S rRNA region — which is why it is described as “mitochondrial-derived” (Lee et al., 2015).

Where is MOTS-c encoded?

It is encoded by a small open reading frame within the 12S ribosomal RNA region of mitochondrial DNA (mtDNA), the mitochondrion’s own separate genome, rather than in the cell nucleus (Lee et al., 2015).

What is a mitochondrial-derived peptide?

A mitochondrial-derived peptide (MDP) is a peptide whose gene sits in mitochondrial DNA rather than the nuclear genome. MOTS-c is one of the most-studied members of this class (Mohtashami et al., 2022).

How is MOTS-c linked to AMPK?

In its founding characterization, researchers reported that MOTS-c acts on the folate (one-carbon) and connected purine-biosynthesis pathway and that this was associated with activation of AMPK — the cell’s central energy-sensing kinase — in mouse and cell models (Lee et al., 2015). This is what the study measured in those research systems.

Has MOTS-c been studied in humans?

The published mechanistic research on MOTS-c is preclinical, carried out in animal and cell-based models. The metabolic, nuclear-translocation, and exercise-related findings cited here were all measured in those research systems, not established in human subjects.

Is MOTS-c the same kind of molecule as a hormone analog?

No. MOTS-c is not a synthetic analog of a known nuclear-encoded hormone. It is an endogenous peptide defined by where it is encoded — the mitochondrial genome — and is studied as a mitochondrial signaling peptide, not a modified version of an existing hormone.

References

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID: 25738459.
2. Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018. PMID: 29983246.
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PMID: 33473109.
4. Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. International Journal of Molecular Sciences. 2022. PMID: 36233287.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

DSIP — delta sleep-inducing peptide — is one of the older entries in the neuropeptide literature, and its name is also the source of a persistent misconception about what it is. The compound was named for an electroencephalogram (EEG) pattern recorded in animals, not for anything it does in a person. This overview covers what DSIP is at the molecular level, where it came from, and what the published research actually measured, framed strictly as what studies reported in their experimental models.

What DSIP is

DSIP is a small neuropeptide — specifically a nonapeptide, meaning a chain of nine amino acids. Its sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE), which has been confirmed by amino-acid analysis and sequence determination of the isolated material and by synthesis of the matching peptide. It is a short, linear, unblocked chain with a free amino terminus and a free carboxyl terminus, and a molecular weight in the region of roughly 850 daltons.

The amino-acid makeup is unremarkable on its own — the residues are all standard, and several of them (the glycines and alanines) are among the smallest and most common in biology. What made the molecule notable was not its chemistry but the experimental context in which it was first detected. It is best described as a neuromodulatory peptide: a substance studied for its capacity to influence the activity of nervous-system tissue rather than to act as a classical hormone or enzyme.

• Class: linear nonapeptide (nine amino acids).
• Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE).
• Approximate molecular weight: on the order of 850 daltons.

How it was discovered

DSIP was first isolated in the mid-1970s by the Schoenenberger–Monnier research group in Basel, Switzerland. The experimental approach was unusual. The investigators induced a slow-wave EEG state in rabbits — in the original work, by low-frequency electrical stimulation of thalamic structures — and then collected and dialyzed the cerebral venous blood from those animals. From that dialysate they purified a peptide fraction that, when administered to recipient rabbits, was reported to reproduce the same EEG pattern.

In the 1977 report of this work, the group described isolating and characterizing the peptide and assigning it the name delta sleep-inducing peptide, after the delta-frequency EEG activity associated with the donor state (Schoenenberger et al., 1977). A follow-up paper completed the structural side of the story, presenting the amino-acid analysis, the nine-residue sequence, the chemical synthesis of that sequence, and a comparison confirming the synthetic peptide matched the natural isolate (Schoenenberger et al., 1978). The name has stuck for fifty years even though, as later authors emphasized, it encodes a conclusion the early data did not fully support.

What the research measured: delta-EEG and sleep models

The defining experiments measured EEG activity in animals, not subjective sleep in people. In the original characterization, intraventricular infusion of the peptide in rabbits was reported to increase slow-wave (delta-frequency) and spindle EEG activity relative to controls, under blinded conditions (Schoenenberger et al., 1977). The endpoint here is an electrophysiological recording — the amount and frequency of slow waves on the EEG trace — not a behavioral or self-reported outcome.

Subsequent work explored how the molecule could be modified. One study examined a phosphorylated analogue of DSIP infused intracerebroventricularly in unrestrained rats and reported increases in measured slow-wave sleep and paradoxical (REM) sleep relative to vehicle, with the phosphorylated form showing greater potency than the parent peptide in that model (Kimura et al., 1989). Again the relevant point is the framing: the study quantified scored sleep stages in instrumented rats, and reported a difference between treated and control animals.

Crucially, the literature on DSIP is not uniform. A broad review of the peptide’s characterization and properties catalogued effects reported across many laboratories — on EEG, on a range of physiological parameters, and on responses to stress — while noting the inconsistency between studies (Schoenenberger et al., 1984). Decades later, a review pointedly titled DSIP “a still unresolved riddle,” summarizing that even basic questions about its mechanism, its endogenous role, and the reproducibility of its sleep-related effects remained open (Kovalzon & Strekalova, 2006). For a research-overview reader, that unresolved status is the most honest single takeaway from the sleep literature.

Beyond sleep: other measured effects in models

Because the early reports described a peptide with diffuse central activity, later research examined endpoints well outside sleep. The Schoenenberger group’s own review described DSIP as having multivariate functions — that is, a range of effects measured across different physiological systems rather than a single tidy action (Schoenenberger et al., 1984).

A more recent example comes from a stroke model. In Sprague-Dawley rats subjected to focal cerebral ischemia by middle cerebral artery occlusion, intranasal administration of DSIP over several days was associated with faster recovery of motor function on rotarod testing compared with vehicle-treated animals, even though the measured infarct volume differed little between groups (Tukhovskaya et al., 2021). This is cited here only to illustrate the breadth of endpoints the peptide has been studied against; it is a measurement made in a rodent injury model, not a statement about any effect in a person.

• EEG endpoints — slow-wave and spindle activity recorded in rabbits (Schoenenberger et al., 1977).
• Scored sleep stages — slow-wave and paradoxical sleep measured in instrumented rats with a modified analogue (Kimura et al., 1989).
• Motor-recovery endpoints — rotarod performance measured in a rat stroke model (Tukhovskaya et al., 2021).

Why the name is misleading

The phrase “sleep-inducing” describes the EEG state of the donor rabbits, not a verified action in any species that received the purified peptide. The slow-wave EEG signature that gave DSIP its name is a correlate, and across half a century of follow-up the connection between that signature and a robust, reproducible sleep effect has remained contested in the literature (Kovalzon & Strekalova, 2006). When reading older sources that treat the name as a description of function, it is worth keeping the distinction in mind: DSIP is named after a recording, and what each study supports is whatever that study specifically measured — an EEG change, a scored sleep stage, a behavioral score — in its own model.

Frequently asked questions

What is DSIP?

DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide (a nonapeptide) with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was isolated in the mid-1970s from research on slow-wave EEG activity in rabbits and is studied as a neuromodulatory peptide.

What does DSIP stand for?

DSIP stands for delta sleep-inducing peptide. The “delta” refers to the delta-frequency slow waves seen on the EEG of the animals from which the peptide was first isolated, not to a verified effect in the recipient.

What is the amino-acid sequence of DSIP?

DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE), confirmed by amino-acid analysis and by synthesis of the matching peptide (Schoenenberger et al., 1978).

Where did DSIP come from?

It was isolated by the Schoenenberger–Monnier group in Basel, Switzerland, in the mid-1970s. They induced a slow-wave EEG state in rabbits, dialyzed the cerebral venous blood, and purified the peptide responsible for reproducing that EEG pattern in recipient animals (Schoenenberger et al., 1977).

What does the research on DSIP actually show?

The published studies report what was measured in laboratory models: increased slow-wave and spindle EEG activity in rabbits (Schoenenberger et al., 1977), increased scored slow-wave and REM sleep in rats given a phosphorylated analogue (Kimura et al., 1989), and a range of other physiological endpoints. Reviews note the results have been inconsistent across laboratories, and one called DSIP “a still unresolved riddle” (Kovalzon & Strekalova, 2006).

Is the “sleep-inducing” name accurate?

The name describes the EEG state of the donor animals rather than a reproducible action in recipients. The link between DSIP and a robust sleep effect has remained contested in the research literature for decades (Kovalzon & Strekalova, 2006).

References

1. Schoenenberger GA, et al. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977. PMID: 265572.
2. Schoenenberger GA, et al. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch. 1978. PMID: 568769.
3. Schoenenberger GA, et al. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984. PMID: 6548966.
4. Kimura M, et al. The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats. Psychopharmacology (Berl). 1989. PMID: 2496423.
5. Kovalzon VM, et al. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID: 16539679.
6. Tukhovskaya EA, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021. PMID: 34500605.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.